Editorial: Volume II: Tumor microenvironment in cancer hallmarks and therapeutics.
作者信息
Shi Rongchen, Gao Yuan, Ferreira José Alexandre, Luo Na, Miao Hongming
机构信息
Frontier Medical Training Brigade, Third Military Medical University (Army Medical University), Xinjiang, China.
Department of Pathophysiology, College of High Altitude Military Medicine, Third Military Medical University (Army Medical University), Chongqing, China.
出版信息
Front Mol Biosci. 2023 Mar 28;10:1182083. doi: 10.3389/fmolb.2023.1182083. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Volume II: Tumor microenvironment in cancer hallmarks and therapeutics.
Front Mol Biosci. 2023 Mar 28;10:1182083. doi: 10.3389/fmolb.2023.1182083. eCollection 2023.
2
Editorial: Tumor microenvironment in cancer hallmarks and therapeutics.
Front Mol Biosci. 2022 Sep 12;9:1019830. doi: 10.3389/fmolb.2022.1019830. eCollection 2022.
3
Editorial: Complexity of tumor microenvironment: A major culprit in cancer development, volume II.
Front Endocrinol (Lausanne). 2023 Jan 12;13:1126778. doi: 10.3389/fendo.2022.1126778. eCollection 2022.
4
Editorial: Women in cancer molecular targets and therapeutics, volume II: 2022.
Front Oncol. 2023 Jul 7;13:1241793. doi: 10.3389/fonc.2023.1241793. eCollection 2023.
5
miRNAs in Regulation of Tumor Microenvironment, Chemotherapy Resistance, Immunotherapy Modulation and miRNA Therapeutics in Cancer.
Int J Mol Sci. 2022 Nov 10;23(22):13822. doi: 10.3390/ijms232213822.
6
Cancer Physical Hallmarks as New Targets for Improved Immunotherapy.
Trends Cell Biol. 2021 Jul;31(7):520-524. doi: 10.1016/j.tcb.2021.03.011. Epub 2021 Apr 27.
7
Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer.
Front Immunol. 2023 Feb 22;14:1054700. doi: 10.3389/fimmu.2023.1054700. eCollection 2023.
8
Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.
Cells. 2019 Sep 14;8(9):1083. doi: 10.3390/cells8091083.
9
Adaptable peptide-based therapeutics modulating tumor microenvironment for combinatorial radio-immunotherapy.
J Control Release. 2021 Dec 10;340:35-47. doi: 10.1016/j.jconrel.2021.10.026. Epub 2021 Oct 24.
10
Combinatorial therapy in tumor microenvironment: Where do we stand?
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188585. doi: 10.1016/j.bbcan.2021.188585. Epub 2021 Jul 2.
本文引用的文献
1
Molecular Biomarkers in Cancer.
Biomolecules. 2022 Jul 23;12(8):1021. doi: 10.3390/biom12081021.
2
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.
Mol Cancer. 2022 Apr 11;21(1):98. doi: 10.1186/s12943-022-01561-5.
3
Cancer Biomarkers for Integrative Oncology.
Curr Oncol Rep. 2019 Mar 5;21(4):32. doi: 10.1007/s11912-019-0782-6.
4
Tumor microenvironment and therapeutic response.
Cancer Lett. 2017 Feb 28;387:61-68. doi: 10.1016/j.canlet.2016.01.043. Epub 2016 Feb 1.
5
Biomarkers predicting tumor response and evasion to anti-angiogenic therapy.
Biochim Biophys Acta. 2012 Jan;1825(1):86-100. doi: 10.1016/j.bbcan.2011.10.004. Epub 2011 Oct 30.
Zotero 插件